<DOC>
	<DOCNO>NCT02793778</DOCNO>
	<brief_summary>The purpose study evaluate CROWN 's efficacy support repair maintenance intestinal mucosa patient moderately severely active Crohn 's Disease receive induction anti-Tumor Necrosis Factor ( TNF ) therapy ( infliximab , adalimumab )</brief_summary>
	<brief_title>Efficacy CROWN Repair Maintenance Intestinal Mucosa Patients With CD Receiving Anti-TNF Therapy</brief_title>
	<detailed_description>The purpose study evaluate effectiveness orally administer medical food ( CROWN ) subject Crohn 's Disease ( CD ) support Standard Of Care ( SOC ) treatment repair maintenance intestinal mucosa 24 week period . SOC define completion induction therapy anti-Tumor Necrosis Factor ( TNF ) agent within 24 week initiation .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Crohn 's Disease patient derive clinical benefit Standard Care therapy , continue evidence incomplete heal intestinal mucosa . 1 . Adults ( 1875 year age ) know history symptomatic CD confirm endoscopy radiology 2 . CDAI score ≤ 300 3 . Active endoscopic disease ( SESCD score ≥ 6 ) document study screen phase SESCD score ≥ 4 isolated ileal disease 4 . Initiation induction infliximab adalimumab therapy within 24 week prior randomization part standard care ( induction must complete prior randomization ) 5 . Able consume oral nutrition 24 week consist two 4 oz ( 120 ml ) serving daily 6 . Able understand inform consent process , willing follow study instruction likely complete require visit procedure , include use electronic device collect study data , home computer tablet internet access complete online food frequency questionnaire , undergo 2 endoscopy 6 month period Subjects one follow criterion exclude participation study : 1 . If female , subject pregnant , nursing , plan become pregnant study period childbearing potential unable unwilling use reliable form contraception study 2 . Fistula known contribute diarrhea 3 . Recent current history bowel obstruction 4 . Stricturing disease evidence bowel dilation proximal stricture image 5 . Anticipated need gastrointestinal surgical therapy next 6 month 6 . Current treatment systemic corticosteroid dose great 20 mg prednisone ( equivalent ) screen 7 . Treatment topical rectal 5aminosalicylic acid topical rectal steroid within 2 week prior screen 8 . Change antimetabolite therapy within 8 week prior randomization 9 . Current treatment antibiotic CD ( ciprofloxacin , metronidazole ) screen 10 . Current ostomy 11 . Serious infection , neoplasia medical condition would interfere participation study , opinion Investigator 12 . Evidence Clostridium difficile infection previous 4 week 13 . History noncompliance clinical protocol 14 . Active participation another CD trial receive investigational product within past 4 week 15 . Diagnosis celiac disease 16 . Known sensitivity milk soy protein 17 . In Investigator 's opinion , subject condition situation make subject unsuitable study participation , may put subject significant risk , may confound study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Gastrointestinal Diseases</keyword>
	<keyword>Intestinal Diseases</keyword>
	<keyword>mucosal heal</keyword>
	<keyword>inflammatory bowel disease</keyword>
	<keyword>Medical Food</keyword>
</DOC>